2021 Fiscal Year Final Research Report
Prion protein signaling induces M2 macrophage polarization and protects from lethal influenza infection in mice
Project/Area Number |
19K08930
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 54030:Infectious disease medicine-related
|
Research Institution | The University of Tokushima |
Principal Investigator |
CHIDA Junji 徳島大学, 先端酵素学研究所, 助教 (20437651)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | インフルエンザ / プリオン蛋白質 / 抗プリオン抗体 / 脳症 / 多臓器不全 |
Outline of Final Research Achievements |
We show here that stimulation of PrPC with anti-PrP mAbs protected mice from lethal infection with IAVs by stimulating macrophage polarization to an anti-inflammatory M2 phenotype through activation of SFKs in infected lungs. IAVs are causative agents for seasonal epidemic outbreaks of influenza, and often cause high morbidity and mortality in infected people, particularly in the young and elderly and those with underlying chronic diseases. The other problem with IAV infections is that new IAV strains, which are resistant to currently available anti-influenza agents such as neuraminidase inhibitors, have been emerging in human populations. Our current results showing that targeting PrPC with anti-PrP mAbs protected against lethal infection with IAVs in mice give rise to the possibility that PrPC-targeting therapeutics might be beneficial in influenza infection.
|
Free Research Field |
ウイルス学
|
Academic Significance and Societal Importance of the Research Achievements |
インフルエンザの重症化機序が明確でない現状で、抗ウイルス薬の一方的な投与が原因で、抗ウイルス薬の耐性株が世界各地で急増している。一方、ワクチンではインフルエンザの感染予防は不可能であると世界保健機関が既に提言している。このような背景から、抗ウイルス薬とは作用機序の異なる「耐性株を出現させない治療薬」の開発が急務であるが、これまで宿主因子を標的とした治療薬の開発は国内外で成功例がない。従って、宿主因子であるPrPを分子標的とした治療薬を開発する試みはこれまでに例がなく、本研究の成果は、今後この方面の研究に大きく貢献することが期待される。
|